{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:31:52Z","timestamp":1760149912339,"version":"build-2065373602"},"reference-count":58,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T00:00:00Z","timestamp":1695427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Science and Technology Projects in Guangzhou","award":["2023A03J0170","2021B1515020043"],"award-info":[{"award-number":["2023A03J0170","2021B1515020043"]}]},{"name":"Guangdong Basic and Applied Basic Research Foundation","award":["2023A03J0170","2021B1515020043"],"award-info":[{"award-number":["2023A03J0170","2021B1515020043"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Chemotherapy-induced side effects restrain anti-tumor efficiency, with hyperlipidemia being the most common accompanying disease to cause treatment failure. In this work, a chimeric peptide-engineered nanomedicine (designated as PRS) was fabricated for the synergistic suppression of tumor growth and therapy-induced hyperlipidemia. Within this nanomedicine, the tumor matrix-targeting peptide palmitic-K(palmitic)CREKA can self-assemble into a nano-micelle to encapsulate Rapamycin (mTOR inhibitor) and SBC-115076 (PCSK9 inhibitor). This PRS nanomedicine exhibits a uniform nano-distribution with good stability which enhances intracellular drug delivery and tumor-targeting delivery. Also, PRS was found to synergistically inhibit tumor cell proliferation by interrupting the mTOR pathway and reducing Rapamycin-induced hyperlipidemia by increasing the production of LDLR. In vitro and in vivo results demonstrate the superiority of PRS for systematic suppression of tumor growth and the reduction of hyperlipidemia without initiating any other toxic side effects. This work proposes a sophisticated strategy to inhibit tumor growth and also provides new insights for cooperative management of chemotherapy-induced side effects.<\/jats:p>","DOI":"10.3390\/pharmaceutics15102377","type":"journal-article","created":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T10:40:22Z","timestamp":1695552022000},"page":"2377","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Chimeric Peptide Engineered Nanomedicine for Synergistic Suppression of Tumor Growth and Therapy-Induced Hyperlipidemia by mTOR and PCSK9 Inhibition"],"prefix":"10.3390","volume":"15","author":[{"given":"Hua","family":"Cai","sequence":"first","affiliation":[{"name":"Department of Geriatric Cardiology, General Hospital of Southern Theater Command, People\u2019s Liberation Army, Guangzhou 510010, China"},{"name":"Graduate School, Guangzhou University of Chinese Medicine, Guangzhou 510006, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongrong","family":"Zheng","sequence":"additional","affiliation":[{"name":"Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ningxia","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Geriatric Cardiology, General Hospital of Southern Theater Command, People\u2019s Liberation Army, Guangzhou 510010, China"},{"name":"Graduate School, Guangzhou University of Chinese Medicine, Guangzhou 510006, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaman","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Geriatric Cardiology, General Hospital of Southern Theater Command, People\u2019s Liberation Army, Guangzhou 510010, China"},{"name":"School of Chemistry and Chemical Engineering, Guangdong Pharmaceutical University, Guangzhou 510006, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9615-7541","authenticated-orcid":false,"given":"Ruixin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Geriatric Cardiology, General Hospital of Southern Theater Command, People\u2019s Liberation Army, Guangzhou 510010, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9242-6225","authenticated-orcid":false,"given":"Jianing","family":"Chi","sequence":"additional","affiliation":[{"name":"Department of Geriatric Cardiology, General Hospital of Southern Theater Command, People\u2019s Liberation Army, Guangzhou 510010, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Chemistry and Chemical Engineering, Guangdong Pharmaceutical University, Guangzhou 510006, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linping","family":"Zhao","sequence":"additional","affiliation":[{"name":"Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Cheng","sequence":"additional","affiliation":[{"name":"Biomaterials Research Center, School of Biomedical Engineering, Southern Medical University, Guangzhou 510515, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Chemistry and Chemical Engineering, Guangdong Pharmaceutical University, Guangzhou 510006, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiying","family":"Li","sequence":"additional","affiliation":[{"name":"Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7750-8011","authenticated-orcid":false,"given":"Lin","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Geriatric Cardiology, General Hospital of Southern Theater Command, People\u2019s Liberation Army, Guangzhou 510010, China"},{"name":"Graduate School, Guangzhou University of Chinese Medicine, Guangzhou 510006, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1056\/NEJMp1113569","article-title":"The burden of disease and the changing task of medicine","volume":"366","author":"Jones","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"ESMO Guidelines Committee. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines: The task force for cancer treatments and cardiovascular toxicity of the European society of cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41569-022-00698-6","article-title":"Cardio-onco-metabolism: Metabolic remodelling in cardiovascular disease and cancer","volume":"19","author":"Karlstaedt","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/eurheartj\/ehaa779","article-title":"Long-term cardiovascular disease mortality among 160,834 5-year survivors of adolescent and young adult cancer: An American population-based cohort study","volume":"42","author":"Wang","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1200\/JCO.2015.65.5845","article-title":"Cardiovascular disease risk profiles in survivors of adolescent and young adult (AYA) cancer: The kaiser permanente AYA cancer survivors study","volume":"34","author":"Chao","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nature04869","article-title":"Ras, PI(3)K and mTOR signalling controls tumour cell growth","volume":"441","author":"Shaw","year":"2006","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"841","DOI":"10.2165\/11585500-000000000-00000","article-title":"Potential synergies for combined targeted therapy in the treatment of neuroendocrine cancer","volume":"71","author":"Salazar","year":"2011","journal-title":"Drugs"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1470-2045(17)30688-5","article-title":"Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"19","author":"Johnston","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.ki.5001853","article-title":"Renal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors","volume":"70","author":"Rakowski","year":"2006","journal-title":"Kidney Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nm1052","article-title":"mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways","volume":"10","author":"Majumder","year":"2004","journal-title":"Nat. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.1182\/blood.V122.21.5117.5117","article-title":"Efficacy and safety of temsirolimus in patients with relapsed or refractory mantle cell lymphoma: Results from the spanish experience","volume":"122","author":"Carbonero","year":"2013","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2020-140507","article-title":"Everolimus plus Itacitinib in relapsed\/refractory classical hodgkin lymphoma: Results of a phase I\/II investigator initiated trial (EVITA Study)","volume":"136","author":"Svoboda","year":"2020","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-12-0110","article-title":"Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients","volume":"18","author":"Cohen","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1200\/JCO.2006.10.5916","article-title":"Phase I\/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma","volume":"25","author":"Motzer","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ando.2018.07.010","article-title":"Expert opinion on the metabolic complications of mTOR inhibitors","volume":"79","author":"Bouillet","year":"2018","journal-title":"Ann. Endocrinol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","article-title":"Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS)","volume":"74","author":"Koskinas","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3091-3091","DOI":"10.1200\/jco.2010.28.15_suppl.3091","article-title":"Fasting glucose and triglycerides as biomarkers of mTOR inhibition, evidence of a categorical response","volume":"28","author":"Nallari","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2337\/db09-1602","article-title":"Mammalian target of rapamycin complex 1 suppresses lipolysis, stimulates lipogenesis, and promotes fat storage","volume":"59","author":"Chakrabarti","year":"2010","journal-title":"Diabetes"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration, Sarwar, N., Sandhu, M.S., Ricketts, S.L., Butterworth, A.S., Di Angelantonio, E., Boekholdt, S.M., Ouwehand, W., Watkins, H., and Samani, N.J. (2010). Triglyceride-mediated pathways and coronary disease: Collaborative analysis of 101 studies. Lancet, 375, 1634\u20131639.","DOI":"10.1016\/S0140-6736(10)60545-4"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/ng.2795","article-title":"Common variants associated with plasma triglycerides and risk for coronary artery disease","volume":"45","author":"Do","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.celrep.2016.03.020","article-title":"Tumor-induced hyperlipidemia contributes to tumor growth","volume":"15","author":"Huang","year":"2016","journal-title":"Cell Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1055\/s-2008-1040405","article-title":"Role of the liver in hyperlipidemia","volume":"12","author":"Havel","year":"1992","journal-title":"Semin. Liver Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1210\/endrev\/bnab035","article-title":"The Multifaceted Biology of PCSK9","volume":"43","author":"Seidah","year":"2022","journal-title":"Endocr. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1172\/JCI61919","article-title":"Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice","volume":"122","author":"Ai","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Fan, G.L., Deng, F.A., Zhou, X., Liu, L.S., Huang, J.Q., Zhang, D.W., Sun, Y.X., Chen, A.L., Cheng, H., and Li, S.Y. (2021). Plasma membrane targeted photodynamic O2 economizer for hypoxic tumor therapy. Biomaterials, 273.","DOI":"10.1016\/j.biomaterials.2021.120854"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.3892\/ijmm.2014.1715","article-title":"The combination of rapamycin and MAPK inhibitors enhances the growth inhibitory effect on Nara-H cells","volume":"33","author":"Nakamura","year":"2014","journal-title":"Int. J. Mol. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1021\/acsmacrolett.9b00146","article-title":"Light-triggered reversible slimming of azobenzene-containing wormlike nanoparticles synthesized by polymerization-induced self-assembly for nanofiltration switches","volume":"8","author":"Guan","year":"2019","journal-title":"ACS Macro Lett."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"10674","DOI":"10.1038\/s41598-023-37884-6","article-title":"Rapamycin prevents lung injury related to acute spinal cord injury in rats","volume":"13","author":"Chu","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Ye, P., Jiang, X.M., Qian, W.C., and Zhang, J. (Cardiovasc. Drugs Ther., 2023). Inhibition of PCSK9 improves the development of pulmonary arterial hypertension via down-regulating notch 3 expression, Cardiovasc. Drugs Ther., Online ahead of print.","DOI":"10.1007\/s10557-023-07458-9"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1242\/jcs.051011","article-title":"mTOR signaling at a glance","volume":"122","author":"Laplante","year":"2009","journal-title":"J. Cell Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41568-018-0074-8","article-title":"mTOR signalling and cellular metabolism are mutual determinants in cancer","volume":"18","author":"Mossmann","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.chembiol.2021.10.006","article-title":"Rapamycin targets STAT3 and impacts c-Myc to suppress tumor growth","volume":"29","author":"Sun","year":"2022","journal-title":"Cell Chem. Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40164-021-00218-1","article-title":"PCSK9 promotes tumor growth by inhibiting tumor cell apoptosis in hepatocellular carcinoma","volume":"10","author":"Zhang","year":"2021","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.3892\/etm.2017.4218","article-title":"PCSK9 regulates apoptosis in human lung adenocarcinoma A549 cells via endoplasmic reticulum stress and mitochondrial signaling","volume":"13","author":"Xu","year":"2017","journal-title":"Exp. Ther. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1593\/neo.121252","article-title":"Proprotein convertase subtilisin\/kexin type 9 deficiency reduces melanoma metastasis in liver","volume":"14","author":"Sun","year":"2012","journal-title":"Neoplasia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41586-020-2911-7","article-title":"Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer","volume":"588","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1142428","DOI":"10.3389\/fimmu.2023.1142428","article-title":"PCSK9 regulates the efficacy of immune checkpoint therapy in lung cancer","volume":"14","author":"Gao","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13046-022-02584-y","article-title":"PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity","volume":"42","author":"Gu","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s13046-022-02477-0","article-title":"PCSK9 promotes the progression and metastasis of colon cancer cells through regulation of EMT and PI3K\/AKT signaling in tumor cells and phenotypic polarization of macrophages","volume":"41","author":"Wang","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s13238-021-00821-2","article-title":"Potentiating CD8+ T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling","volume":"12","author":"Yuan","year":"2021","journal-title":"Protein Cell"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1172\/JCI97712","article-title":"MAPK4 overexpression promotes tumor progression via noncanonical activation of AKT\/mTOR signaling","volume":"129","author":"Wang","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1039\/C5MB00101C","article-title":"The PI3K\/AKT\/mTOR interactive pathway","volume":"11","author":"Ersahin","year":"2015","journal-title":"Mol. Biosyst."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.ctrv.2013.03.009","article-title":"Targeting the PI3K\/AKT\/mTOR and Raf\/MEK\/ERK pathways in the treatment of breast cancer","volume":"39","author":"Saini","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"ref_48","first-page":"3065","article-title":"Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer","volume":"118","author":"Carracedo","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1038\/jid.2008.44","article-title":"Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells","volume":"128","author":"Lasithiotakis","year":"2008","journal-title":"J. Investig. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.drup.2007.03.003","article-title":"Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies","volume":"10","author":"Tortora","year":"2007","journal-title":"Drug Resist. Updat."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ccr.2005.09.006","article-title":"The BAD protein integrates survival signaling by EGFR\/MAPK and PI3K\/Akt kinase pathways in PTEN-deficient tumor cells","volume":"8","author":"She","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3389\/fonc.2020.609663","article-title":"Proprotein convertase subtilisin\/kexin type 9 promotes gastric cancer metastasis and suppresses apoptosis by facilitating MAPK signaling pathway through HSP70 up-regulation","volume":"10","author":"Xu","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1016\/j.cell.2022.09.023","article-title":"The JAK-STAT pathway at 30: Much learned, much more to do","volume":"185","author":"Philips","year":"2022","journal-title":"Cell"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"20587384211038345","DOI":"10.1177\/20587384211038345","article-title":"Pro-protein convertase subtilisin\/kexin type 9 promotes intestinal tumor development by activating janus kinase 2\/signal transducer and activator of transcription 3\/SOCS3 signaling in ApcMin\/+ mice","volume":"35","author":"Yang","year":"2021","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jncc.2020.12.001","article-title":"Cancer incidence and mortality in China, 2015","volume":"1","author":"Zhang","year":"2021","journal-title":"J. Natl. Cancer Cent."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Andrade, M.L., Gilio, G.R., Perandini, L.A., Peixoto, A.S., Moreno, M.F., Castro, \u00c9., Oliveira, T.E., Vieira, T.S., Ortiz-Silva, M., and Thomazelli, C.A. (2021). PPAR\u03b3-induced upregulation of subcutaneous fat adiponectin secretion, glyceroneogenesis and BCAA oxidation requires mTORC1 activity. Biochim. Biophys. Acta Mol. Cell Biol. Lipids, 1866.","DOI":"10.1016\/j.bbalip.2021.158967"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration, Baigent, C., Blackwell, L., Emberson, J., Holland, L.E., Reith, C., Bhala, N., Peto, R., Barnes, E.H., and Keech, A. (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 376, 1670\u20131681.","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1093\/eurheartj\/ehx566","article-title":"Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: A meta-analysis of randomized trials","volume":"39","author":"Koskinas","year":"2018","journal-title":"Eur. Heart J."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/10\/2377\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:56:53Z","timestamp":1760129813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/10\/2377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,23]]},"references-count":58,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["pharmaceutics15102377"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics15102377","relation":{},"ISSN":["1999-4923"],"issn-type":[{"type":"electronic","value":"1999-4923"}],"subject":[],"published":{"date-parts":[[2023,9,23]]}}}